Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Veradermics, Incorporated
MANE
NYSE·Healthcare·Biotechnology·Mkt cap $5.4B
$128.83
▲ +0.27%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$32.00 - $131.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 240.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary dissolvable microarray patch technology platform
- Non-hormonal, oral treatment approach for pattern hair loss
- Focus on underserved pediatric dermatology populations
- Diverse pipeline reducing single-product risk
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Revenue decline expected
Clinical trial progression and regulatory approvals for VDPHL01
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+100.2% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MANE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 15, 2026
MAY 12, 2026
Reported EPS of -$1.32 vs -$0.56 consensus (-135.7% surprise).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-135.7%
Next: May 15, 2026
Revenue trend · last 2Q
—
—
Q4 24
Q1 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$136.00
▲ +5.6% vs $128.83
Latest: Needham · $136.00 · Jun 2, 2026
1 analyst covering
vs Industry
How MANE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related
Peers & themes
Peers
No peer data available.
Themes
No themes assigned.